Although the initial excitement from the approval of sotorasib and adagrasib has died down due to the realization of their limitations in the clinic, there is a large body of evidence to support the hope that combining KRAS inhibitors with immunotherapies may be able to provide significantly improved outcomes in the treatment of KRAS mutant cancers. The gene discussed is KRAS; the disease is cancer.